FMED - ETF AI Analysis
Top Page
Fidelity Disruptive Medicine ETF (FMED)
FMED’s rating suggests it is a solid but somewhat risky choice, reflecting both promising growth stories and notable financial challenges among its holdings. Strong contributors like Danaher and Argenx support the fund with healthy financial performance, robust revenue growth, and positive momentum, while weaker names such as Revolution Medicines and Moderna, which face declining revenues, losses, and bearish or volatile trends, weigh on the overall assessment. The main risk is the fund’s focus on disruptive medicine and biotech, where many companies are unprofitable and valuations can be high, leading to potentially large price swings.
FMED vs. SPDR S&P 500 ETF (SPY)
- AUM
- 54.39M
- Region
- Global
- Expense Ratio
- 0.50%
- Beta
- 0.84
- Issuer
- Fidelity
- Inception Date
- Jun 12, 2023
- Dividend Yield
- 0.35%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
FMED Summary
The Fidelity Disruptive Medicine ETF (FMED) focuses on innovative healthcare companies, especially in areas like biotechnology, genomics, and digital health. It does not track a traditional index, but instead follows the theme of “disruptive medicine,” aiming to invest in firms driving the future of medical treatments and technology. Well-known holdings include Thermo Fisher and Danaher, along with specialized companies such as Illumina and 10x Genomics. Someone might invest in FMED for long-term growth and diversification within cutting-edge healthcare. A key risk is that these medical innovation stocks can be volatile and may go up and down more than the overall market.
How much will it cost me?
FMED has an expense ratio of 0.50%, which means you’ll pay about $5 per year for every $1,000 invested. This cost is higher than the average ETF because it’s actively managed and focuses on a specialized, disruptive medicine strategy rather than simply tracking a broad market index.
What would affect this ETF?
FMED could benefit if global healthcare spending grows, new medical technologies like genomics and precision medicine gain wider adoption, and supportive regulations help innovative companies such as 10x Genomics, Natera, and Moderna bring new treatments to market. On the other hand, it could be hurt by tighter drug and device regulations, setbacks in clinical trials, higher interest rates that make riskier growth stocks less attractive, or economic slowdowns that pressure funding and valuations across the global healthcare sector.
FMED Top 10 Holdings
FMED is a pure play on disruptive healthcare, with its top names almost entirely in biotech and life sciences and a global mix that leans heavily on U.S. innovators. Thermo Fisher and Danaher provide a steadier backbone, rising modestly and helping smooth out volatility. Illumina and Natera are climbing as genomics and precision medicine regain investor interest, giving the fund some welcome tailwind. On the flip side, 10x Genomics and Revolution Medicines have been lagging lately, so their early-stage risk can tug on performance when sentiment toward high-growth biotech cools.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TXG | 10x Genomics | 4.87% | $2.65M | $9.13B | 463.59% | 60Neutral |
 NTRA | Natera | 4.49% | $2.44M | $59.72B | 114.42% | 73Outperform |
 TMO | Thermo Fisher | 4.17% | $2.27M | $257.71B | 25.31% | 72Outperform |
 DHR | Danaher | 3.92% | $2.13M | $163.38B | 7.99% | 75Outperform |
 ILMN | Illumina | 3.63% | $1.97M | $35.63B | 138.35% | 71Outperform |
 LFST | Lifestance Health Group | 2.87% | $1.56M | $5.12B | 172.91% | 61Neutral |
 FR:DIM | Sartorius Stedim Biotech | 2.81% | $1.53M | EUR 21.74B | 8.03% | 61Neutral |
 ARGX | Argenx Se | 2.64% | $1.44M | $56.88B | 8.84% | 79Outperform |
 RVMD | Revolution Medicines | 2.52% | $1.37M | $41.00B | 224.97% | 52Neutral |
 HTFL | HeartFlow, Inc. | 2.50% | $1.36M | $5.13B | 61.47% | 40Neutral |
FMED Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FMED, the sentiment is Positive. The current price of 32.41 is above the 20-day moving average (MA) of 31.58, above the 50-day MA of 31.77, and above the 200-day MA of 27.78, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 54.70 is Neutral, neither overbought nor oversold. The STOCH value of 83.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FMED.
FMED Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FMED | $32.41 | $32.00(-1.27% Downside) | $54.39M | 0.50% | 59Neutral |
 MEDI | $35.20 | $45.57(29.44% Upside) | $45.93M | 0.80% | 62Neutral |
 TMED | $34.34 | $56.42(64.32% Upside) | $34.83M | 0.44% | 61Neutral |
 MEDX | $38.25 | $44.13(15.38% Upside) | $17.76M | 0.85% | 65Neutral |
 BMED | $36.50 | $39.32(7.74% Upside) | $14.68M | 0.55% | 65Neutral |
 HLTH | $28.67 | $37.83(31.95% Upside) | $12.63M | 0.75% | 55Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FMED | Fidelity Disruptive Medicine ETF | 32.41 | 6.40 | 24.59% | |
| MEDI | Harbor Health Care ETF | 35.20 | 5.26 | 17.58% | |
| TMED | T. Rowe Price Health Care ETF | 34.34 | 6.02 | 21.27% | |
| MEDX | Horizon Kinetics Medical ETF | 38.25 | 7.48 | 24.29% | |
| BMED | Future Health ETF | 36.50 | 8.30 | 29.45% | |
| HLTH | Tema Healthcare AI ETF | 28.67 | 3.36 | 13.28% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.